{"nctId":"NCT00264550","briefTitle":"An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","startDateStruct":{"date":"2005-12"},"conditions":["Rheumatoid Arthritis"],"count":444,"armGroups":[{"label":"Group 1: Placebo + Methotrexate","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Methotrexate","Drug: Placebo injection"]},{"label":"Group 2: Golimumab 100 mg + Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 100 mg","Drug: Placebo capsules"]},{"label":"Group 3: Golimumab 50 mg + Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 50 mg","Drug: Methotrexate"]},{"label":"Group 4: Golimumab 100 mg + Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 100 mg","Drug: Methotrexate"]}],"interventions":[{"name":"Golimumab 100 mg","otherNames":[]},{"name":"Golimumab 50 mg","otherNames":[]},{"name":"Methotrexate","otherNames":[]},{"name":"Placebo injection","otherNames":[]},{"name":"Placebo capsules","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ACR) for at least 3 months prior to screening\n* Must have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have a MTX dose of \\>=15 mg/week and \\<=25 mg/week and stable for at least 4 weeks prior to screening\n* Have active RA as defined by persistent disease activity with at least 4 swollen and 4 tender joints, at the time of screening and baseline, and at least 2 of the following 4 criteria: a)C-reactive protein (CRP) \\>=1.5 mg/dL at screening or erythrocyte sedimentation rate (ESR) by Westergren method of \\>= 28 mm in the first hour at screening or baseline, b)Morning stiffness of \\>= 30 minutes at screening and baseline, c)Bone erosion by x-ray and/or magnetic resonance imaging (MRI) prior to first administration of study agent, d)Anti-cyclic citrullinated peptide (anti-CCP) antibody-positive or rheumatoid factor (RF) positive at screening\n* If using oral corticosteroids, must be on a stable dose equivalent to \\<= 10 mg of prednisone/day for at least 2 weeks prior to first administration of study agent\n* Are considered eligible according to specified tuberculosis (TB) screening criteria\n\nExclusion Criteria:\n\n* Have inflammatory diseases other than RA that might confound the evaluation of the benefit of golimumab therapy\n* Have had treatment with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than MTX, during the 4 weeks prior to the first administration of study agent\n* Have had prior treatment with biologic anti-tumor necrosis factor (TNF) drugs (infliximab, etanercept, adalimumab)\n* Have had history of, or ongoing, chronic or recurrent infectious disease.\n* Have serious infection within 2 months prior to first administration of study agent\n* Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14","description":"ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"50","spread":null},{"groupId":"OG004","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14","description":"DAS 28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis which combines tender joint count (28 joints), swollen joint count (28 joints), CRP value, and participant's global assessment of disease activity (using a Visual Analog Scale of 0 to 100 mm). The DAS 28 score ranges from 0 (best) to 10 (worst). Participants are considered to have a DAS 28 response if they have a score of \\<= 3.2 (good response) or \\> 3.2 to 5.1 (moderate response).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"67","spread":null},{"groupId":"OG004","value":"131","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24","description":"HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1250","spread":null},{"groupId":"OG001","value":"0.1250","spread":null},{"groupId":"OG002","value":"0.3750","spread":null},{"groupId":"OG003","value":"0.5000","spread":null},{"groupId":"OG004","value":"0.4375","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24","description":"An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"53","spread":null},{"groupId":"OG004","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14","description":"The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1250","spread":null},{"groupId":"OG001","value":"0.2500","spread":null},{"groupId":"OG002","value":"0.3750","spread":null},{"groupId":"OG003","value":"0.3750","spread":null},{"groupId":"OG004","value":"0.3750","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24","description":"The vdH-S score is the sum of joint erosion score and joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"2.354"},{"groupId":"OG001","value":"0.00","spread":"1.598"},{"groupId":"OG002","value":"0.00","spread":"2.740"},{"groupId":"OG003","value":"0.00","spread":"1.342"},{"groupId":"OG004","value":"0.00","spread":"2.159"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":105},"commonTop":["Upper Respiratory Tract Infection","Nasopharyngitis","Bronchitis","Cough","Pharyngitis"]}}}